Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials

Arthritis and Rheumatology

Volumn 68, Issue 9, 2016, Pages 2184-2192

  van Vollenhoven, Ronald F ^a   Petri, Michelle ^b   Wallace, Daniel J ^c   Roth, David A ^d   Molta, Charles T ^d   Hammer, Anne E ^d   Tang, Yongqiang ^d   Thompson, April ^d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BELIMUMAB; CORTICOSTEROID; PLACEBO;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTHRALGIA; ARTHRITIS; ARTICLE; BACKACHE; BRONCHITIS; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; COUGHING; CYSTITIS; DIARRHEA; DISEASE ACTIVITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SAFETY; DYSPNEA; EDEMA; FATIGUE; FEMALE; FEVER; GASTRITIS; GASTROENTERITIS; HEADACHE; HUMAN; HYPERTENSION; HYPOKALEMIA; INFESTATION; INFLUENZA; INSOMNIA; LIMB PAIN; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MYALGIA; NAUSEA; NONCARDIAC CHEST PAIN; OROPHARYNX PAIN; PERIPHERAL EDEMA; PHARYNGITIS; PNEUMONIA; POST HOC ANALYSIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINOPHARYNGITIS; SAFETY OF ESTROGENS IN LUPUS ERYTHEMATOSUS NATIONAL ASSESSMENT; SENSITIVITY ANALYSIS; SIDE EFFECT; SINUSITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRAL GASTROENTERITIS; VOMITING; WEIGHT GAIN;

EID: 84983472865     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39682     Document Type: Article

References (22)

1. Urowitz MB, Gladman DD, Ibañez D, Fortin PR, Bae SC, Gordon C, et al. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken) 2012;64:132–7.
2. Fangtham M, Petri M. 2013 update: Hopkins Lupus Cohort. Curr Rheumatol Rep 2013;15:1–7.
3. Bexelius C, Wachtmeister K, Skare P, Jönsson L, van Vollenhoven R. Drivers of cost and health-related quality of life in patients with systemic lupus erythematosus (SLE): a Swedish nationwide study based on patient reports. Lupus 2013;22:793–801.
4. Watson P, Brennan A, Birch H, Fang H, Petri M. An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins Lupus Cohort. Rheumatology (Oxford) 2015;54:623–32.
5. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams L, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408–15.
6. Gustafsson J, Gunnarsson I, Borjesson O, Pettersson S, Moller S, Fei GZ, et al. Predictors of the first cardiovascular event in patients with systemic lupus erythematosus: a prospective cohort study. Arthritis Res Ther 2009;11:R186.
7. Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol 2012;176:708–19.
8. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000;43:1801–8.
9. Ravelli A, Duarte-Salazar C, Buratti S, Reiff A, Bernstein B, Maldonado-Velazquez MR, et al. Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study. Arthritis Rheum 2003;49:501–7.
10. Gladman DD, Urowitz MB, Rahman P, Ibañez D, Tam LS. Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003;30:1955–9.
11. Petri M, Purvey S, Fang H, Magder LS. Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum 2012;64:4021–8.
12. Thamer M, Hernán MA, Zhang Y, Cotter D, Petri M. Relationship between prednisone, lupus activity and permanent organ damage. J Rheumatol 2009;36:560–4.
13. Al Sawah S, Zhang X, Zhu B, Magder LS, Foster SA, Iikuni N, et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus—the Hopkins Lupus Cohort. Lupus Sci Med 2015;2:e000066.
14. European Medicines Association. Guideline on clinical investigation of medicinal products for the treatment of systemic lupus erythematosus, cutaneous lupus and lupus nephritis. May 2013. URL: http://www.ema.europa.eu/ema/doc_index.jsp?curl=pages/includes/document/document_detail.jsp?webContentId=WC500139615&murl=menus/document_library/document_library.jsp&mid=0b01ac058009a3dc.
15. Van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrom K, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 2014;73:958–67.
16. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003;48:3253–65.
17. Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721–31.
18. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, et al, for the BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918–30.
19. Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR recommendations for the management of systemic lupus erythematosus: report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 2008;67:195–205.
20. Biesen R, Dahnrich C, Rosemann A, Barkhudarova F, Rose T, Jakob O, et al. Anti-dsDNA-NcX ELISA: dsDNA-loaded nucleosomes improve diagnosis and monitoring of disease activity in systemic lupus erythematosus. Arthritis Res Ther 2011;13:R26.
21. Petri MA, Lahita RG, van Vollenhoven RF, Merrill JT, Schiff M, Ginzler EM, et al, for the GL701 Lupus Study Group. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2002;46:1820–9.
22. Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, et al. The efficacy and safety of abatacept in patients with non–life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:3077–87.